Versiti

What it reported doing in 2024

Msi: the versiti medical services institute (msi) advances patient care through specialized treatment and translational research that bridges clinical medicine and laboratory science, fostering collaboration between physician-scientists and basic researchers to accelerate medical discoveries. Established in 2009 and supported by versiti and the versiti blood research institute foundation, msi enables physicians to dedicate protected time to clinical research while maintaining patient care responsibilities. In 2024, versiti physician-scientists performed 3,686 therapeutic procedures. As part of versiti's mission to advance evidence-based medicine, msi operates the clinical trials & research office (ctro) to conduct fda-regulated clinical studies in specialized areas including alloimmune platelet disorders, transfusion-induced acute lung injury, and drug-induced blood disorders. Through mentorship, protected research time, and collaborative infrastructure, msi provides deep clinical expertise and transforms clinical questions into scientific discoveries that benefit patients with blood disorders nationwide.donor testing: the versiti donor testing laboratory (dtl) provides infectious disease testing to determine donor suitability and product safety for organs, tissues, hematopoietic stem cells, and cord blood. The dtl offers nucleic acid testing, antibody screening, and confirmatory testing for many different disease states. As part of versiti's mission to maintain the safest possible blood supply, donor testing operations conduct mandatory screening for transfusion-transmissible infections as required by fda regulations. The dtl utilizes state-of-the-art nucleic acid testing (nat) technology and serological methods to detect infectious agents. Versiti's dtl supports blood collection activities across versiti's entire geographic footprint while maintaining rigorous quality standards and regulatory compliance. Versiti's donor testing services strengthen the national blood supply infrastructure. By ensuring comprehensive donor screening, versiti protects patients who depend on safe blood transfusions, strengthens the national blood supply, and supports the broader public health mission of maintaining confidence in a high-quality blood supply.diagnostic labs: versiti serves patients, physicians, and hospitals by providing comprehensive clinical diagnostic testing services that support accurate diagnosis, treatment monitoring, and patient care across multiple medical specialties. As part of versiti's mission to advance healthcare through laboratory excellence, the diagnostic laboratories deliver specialized testing services including hematology, coagulation, immunohematology, infectious disease, molecular diagnostics, flow cytometry, and reference laboratory services. During 2024, versiti conducted 148,545 diagnostic testing services for hospitals, physician offices, and reference laboratories. Versiti's diagnostic laboratories maintain state-of-the-art instrumentation and rigorous quality assurance programs to ensure accurate, timely results that guide clinical decision-making and improve patient outcomes. The laboratories provide specialized expertise in blood-related disorders, offering advanced testing capabilities including platelet function analysis, coagulation studies, red blood cell antigen typing, and complex immunohematology workups that confirm and ensure transfusion safety. Versiti's diagnostic laboratories serve as a vital healthcare infrastructure resource, providing 24/7 testing support for emergency departments and critical care units. Through comprehensive diagnostic testing services, advanced laboratory expertise, and commitment to quality, versiti's diagnostic laboratories strengthen the healthcare system by enabling accurate diagnosis and optimal patient care across the state.organ and tissue: versiti organ and tissue operates as southeastern Wisconsin's federally designated organ procurement organization, coordi

Financial Efficiency

• Mission deployment rate: 81.7%; rating input score 82
• Program expense ratio: 86.7%; rating input score 87
• Fundraising efficiency: Limited

Transparency & Controls

• Consistency checks: 94.7%; rating input score 95; 33rd percentile among comparable filings
• Pay-setting controls: 5 of 6 controls in place; rating input score 83
  • Compensation committee: Pass
  • Independent consultant: Pass
  • Other Form 990s reviewed: Pass
  • Written employment contract: Missing
  • Compensation survey or study: Pass
  • Board or committee approval: Pass
• Foreign activity oversight: Limited
• Grant itemization coverage: 97.9%; rating input score 98; 33rd percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Yes; rating input score 100

Accountability

• Independent voting board: 94.4%; rating input score 94; 46th percentile among comparable filings
• Governance controls: 9 of 9 controls in place; rating input score 100
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: 6.2%; rating input score 61; 61st percentile among comparable filings
• Total-asset coverage ratio: 0.81; rating input score 32; 32nd percentile among comparable filings
• Liabilities to assets ratio: 0.35; rating input score 50; 50th percentile among comparable filings
• Officer compensation ratio: 2.9%; rating input score 40; 40th percentile among comparable filings

Growth

• Program expense growth: 5.3% per year; rating input score 100; 43rd percentile among comparable filings
• Revenue growth: 4.6% per year; rating input score 100; 38th percentile among comparable filings
• Asset growth: 2.5% per year; rating input score 100; 18th percentile among comparable filings